Plus Therapeutics (PSTV) Return on Sales (2011 - 2026)

Plus Therapeutics (PSTV) has 14 years of Return on Sales data on file, last reported at 0.07% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.07%, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04% (down 1.0% YoY), and the FY2025 annual result was 0.03%, down 1.0% from the prior year.
• Return on Sales slipped to 0.07% in Q1 2026 per PSTV's latest filing, from 0.04% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q3 2023 and troughed at 0.72% in Q3 2022.
• A 5-year average of 0.1% and a median of 0.03% in 2025 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 71 bps in 2023 and fell as far as 5 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.44% in 2022, then jumped by 93 bps to 0.03% in 2023, then rose by 5 bps to 0.03% in 2024, then tumbled by 51 bps to 0.04% in 2025, then slumped by 62 bps to 0.07% in 2026.
• Business Quant data shows PSTV's Return on Sales at 0.07% in Q1 2026, 0.04% in Q4 2025, and 0.03% in Q3 2025.